Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - June 2025

Why driving results from such strategies—amid industry disruption—will be critical to success.

Building Agility and Adaptability Into Pharma Operations

The advantages and challenges associated with structuring a patient assistance program as a non-profit foundation.

Changing the PAP Model

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

Popping the Gross-to-Net Bubble, Part IV: Extreme Examples of Who Grew the Bubble

Articles

Pharma Pulse 6/10/25: Exploring Perspectives of Fair Market Value in Clinical Trial Budgeting; New Technology Helps Prevent Opioid Overdose

In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

Sanofi to Begin Globally Shipping Beyfortus Ahead of RSV Season

Videos

Ron Lanton, Partner, Lanton Law, weighs in on the potential international trade, pricing, and access implications of tying US drug costs to those in other developed countries under the Most Favored Nation executive order.

How MFN Executive Order Could Affect International Drug Costs

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Bridging the Gap Between Strategy and Practice in IDN Partnerships

Pharma Pulse 6/9/25: Accelerating Site Activation and Recruitment with MCRC Partnerships; Avenzo Begins Phase I/II Trial of CDK4 Selective Inhibitor for Breast Cancer

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of Medicaid coordination and integration.

The Variation in Dual-Eligible Beneficiary Characteristics across Medicare Advantage Plan Types

In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s data reveals about the relationship between pharmacy access and broader health disparities in underserved communities.

Mapping the Hidden Costs

Pharma Pulse 6/6/25: GLP-1 Drugs May be Linked to Elevated Risk of Serious Eye Disease; Incyte’s Zynyz Wins FDA Approval as Single and Combo Therapy for Anal Cancer

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

BioNTech, BMS to Co-Design and Co-Commercialize New Antibody Candidate for Various Types of Tumors

In the first part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, explains how geospatial mapping can help identify and address emerging pharmacy deserts across the United States.

Featured Content

Pharmaceutical Commerce - June 2025

Building Agility and Adaptability Into Pharma Operations

Changing the PAP Model

Popping the Gross-to-Net Bubble, Part IV: Extreme Examples of Who Grew the Bubble